{"name":"Tempero Bio, Inc.","slug":"tempero-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TMP-301","genericName":"TMP-301","slug":"tmp-301","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"TMP-301","genericName":"TMP-301","slug":"tmp-301","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-11-20","type":"pipeline","source":"PR Newswire","summary":"Alcohol Use Disorder Market to Grow Rapidly at a 13.6% CAGR by 2034 Owing to Rising Disease Prevalence, Significant Advancements in Genetically-targeted Therapies, along with Innovative Treatments suc","headline":"Alcohol Use Disorder Market to Grow Rapidly at a 13.6% CAGR by 2034 Owing to Rising Disease Prevalence, Significant Adva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9PNU1SeXR4czNOTTdMRE52RU5xUmxhTmFDcG9WNnF2Wk1oWDgwbV82Um13aU5JT0dyNEhUV0pjeGJhSWVQblNiUFQzdmc3aUQwZk13U2tn?oc=5","date":"2025-04-02","type":"pipeline","source":"The Pharma Letter","summary":"Tempero Bio - The Pharma Letter","headline":"Tempero Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPUjY2SW9vcXVYQmFoZkFmNW01blFUQ0dTQXU0YWRmSndibVpGS0hnM1RZZTJkN1FrdjAzNGhZTEhyaGQxdVBsVXo4TGR5N2JBNDdjdzNHOVU2bUNiMWlMM0NpS0lrRDUtN19OMjFvd1d4aGliMzlhSFI5NnNDRDBMRkZ2eElrUTdrbWhfLWlnTGg?oc=5","date":"2025-03-24","type":"pipeline","source":"BioPharma Dive","summary":"Tempero Bio gets $70M to advance substance abuse treatment - BioPharma Dive","headline":"Tempero Bio gets $70M to advance substance abuse treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOb0phQmU2ZGEyQ3gxSG1kMGludVZYbDdaaVRkRF9aeWV6Q0k4ZWVTUmRIdTk0azlmMVdxVzEzczBJdlltbklBUzlDRlA3RzhFcEVVN3NaMW9JcFIxb0VNM0tvTU1ETDFGRjctRUFfV3Q3NTNDSmhndXJtRzB5VVA1QnJrVm5VYWhZRG9wX0prTVEza00zQVU3ZlFHZHlINnFxWGV5MDR4aFlfS2dqTXV6Q0hObDUxMkZLR2lmLTI3QnQ1TGRsb0gwRnpxaVl6MW1lWnhsanc2ejZ3N291UnhGTGF0UDlLS3ZfajVxNVpueWZJQnZsUEUxYjhObmtwS1hXLVE?oc=5","date":"2025-03-24","type":"trial","source":"PR Newswire","summary":"Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders - PR Newswire","headline":"Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxNNmV2a0gtQjhKeDk5alZZNFI5dW5pdWxmZl8zZ3ZDVmJFd1U2WnAzUVJKNkhZZVlHYTBlVVFEaUc5Y0FFZGZXNHlGdlJaUVotRGFVUklobzRRcmhINXlQOFQxb1ZOY0JMNlI3X2xwdnhNZmc3QlRldkhFeXdqb3RjX1JiSTZOLURBXzVrM3ZKcVBQWUVOVWhNV2YtdVpvWGNOTFd0Vmh0RDgxZFcwaUNuN0ZJQkhZZ2owUV9fazJRWEt3NXJOcGFNc1ZoXzVhTC11ODVMTkJVYjhSQjhNbXczYldnUnZrMXRvM0dPQ3lSWTYycVFRU3RCeXV3TElyUXZPS085NVZOcjJoaUhIeUZTaGJ5MFdWZEJpRFY5c1JuNlhmTUhlLVFvV3B3RkRTVlc1LWwxZw?oc=5","date":"2023-01-04","type":"regulatory","source":"PR Newswire","summary":"Tempero Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TMP-301 for the Treatment of Alcohol and Other Substance Use Disorders - PR Newswire","headline":"Tempero Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TMP-301 for the Treatment of Alcoh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE92YmlKaTRMUDBpVkt6TU9KLVBIM3hjMTVZcUZiSnFpTkx6aV93LTNzYjVDYVVLYnNQZGUyTFh1LWctbGFEdG1ZQXF0MDNhM2FHNzhpVVZhaTRJZjI1dzFR?oc=5","date":"2022-02-01","type":"pipeline","source":"nature.com","summary":"Edward F. Domino, Ph.D. (1924–2021) - nature.com","headline":"Edward F. Domino, Ph.D. (1924–2021)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOYldRdEVmWVE5TEhzV0lEWEs0dk1KU2s4c1VXY0s5WXZYRGtTQ0tsQkpBWkZuenpYN0hFQ19HYWd5elREelhEa1dsRUhlUHBVVnpSOUNwTFBIQlg2Rzg0VC11VkppVllJS05SVFJ4LUV0cEJFR3N6elU4S2dWRU8xZ2hwNlpaM2FlUF8tdGVGUUVhTk96bGJVVC1WZVN3UExleDRGZDJ3RW1XNmFtU0pWVmd2Tk43ZDBIRUFnS0JvVTlySUtMVC1JUW9Rbkd1cFNNVi1fRnF6empmaS1KVUV6OWoxSm1fZw?oc=5","date":"2020-11-02","type":"pipeline","source":"PR Newswire","summary":"Aditum Bio, Co-Founded by Novartis Veterans Joe Jimenez and Dr. Mark Fishman, forms Second Company - PR Newswire","headline":"Aditum Bio, Co-Founded by Novartis Veterans Joe Jimenez and Dr. Mark Fishman, forms Second Company","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}